Top Page
Sino Biopharmaceutical
(OTC:1177)
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Sino Biopharmaceutical Business Overview & Revenue Model
Sino Biopharmaceutical Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.87B | 26.20B | 28.78B | 26.86B | 23.65B |
| Gross Profit | 23.53B | 21.21B | 22.98B | 21.53B | 18.46B |
| EBITDA | 6.11B | 6.98B | 6.69B | 19.87B | 6.54B |
| Net Income | 3.50B | 2.33B | 5.00B | 14.61B | 4.34B |
Balance Sheet | |||||
| Total Assets | 65.41B | 63.60B | 64.06B | 60.54B | 47.21B |
| Cash, Cash Equivalents and Short-Term Investments | 14.60B | 14.12B | 16.92B | 15.79B | 16.43B |
| Total Debt | 9.78B | 12.58B | 13.98B | 12.12B | 14.21B |
| Total Liabilities | 22.63B | 25.43B | 26.12B | 22.81B | 24.79B |
| Stockholders Equity | 31.96B | 30.47B | 29.75B | 30.29B | 16.75B |
Cash Flow | |||||
| Free Cash Flow | 5.22B | 4.36B | 4.56B | 3.47B | 3.47B |
| Operating Cash Flow | 6.62B | 6.07B | 6.27B | 5.37B | 5.33B |
| Investing Cash Flow | -1.71B | -756.98M | -4.07B | -2.52B | -7.85B |
| Financing Cash Flow | -6.32B | -6.55B | -3.19B | -3.23B | 2.23B |
Sino Biopharmaceutical Technical Analysis
Sino Biopharmaceutical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | 70.73B | 28.73 | 13.54% | 0.86% | 7.51% | 44.09% | |
73 Outperform | 159.64B | 35.04 | 8.03% | ― | 16.90% | 63.11% | |
68 Neutral | $142.18B | 35.89 | 11.72% | 1.13% | 13.69% | 50.71% | |
55 Neutral | 159.71B | 125.54 | -0.72% | ― | 52.78% | ― | |
54 Neutral | 42.00B | -26.11 | -21.86% | ― | 44.21% | 46.11% | |
45 Neutral | 122.24B | -130.35 | -7.55% | ― | 33.46% | -7.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3142, a novel PROTAC molecule targeting Bcl-xL protein for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug is designed to induce apoptosis in tumor cells with a reduced risk of platelet toxicity, offering a promising new treatment option in a field where no Bcl-xL inhibitors are currently approved worldwide.
Sino Biopharmaceutical Limited announced that its Investigational New Drug application for TQB3122, a PARP1 inhibitor designed for treating advanced malignant tumors, has been accepted by China’s National Medical Products Administration. This innovative drug shows promise due to its high selectivity and ability to penetrate the blood-brain barrier, potentially offering new treatment options for intracranial tumors. The acceptance of this application marks a significant step for the company, as there are currently no approved drugs worldwide targeting the same mechanism, positioning Sino Biopharmaceutical as a potential leader in this niche market.
Sino Biopharmaceutical Limited has announced that its subsidiary, LaNova Medicines, has received approval from China’s National Medical Products Administration to conduct Phase II clinical trials for LM-24C5, a CEACAM5/4-1BB bispecific antibody. This innovative drug targets CEACAM5-positive advanced solid tumors and shows promise in enhancing anti-tumor activity by redirecting immune cells to the tumor microenvironment. The approval marks a significant step in the company’s efforts to develop a First-in-Class immunotherapy, potentially strengthening its position in the oncology treatment market.
Sino Biopharmaceutical announced that its independently developed Rovadicitinib Tablet, a JAK/ROCK inhibitor, has been included in the Breakthrough Therapeutic Designation process by China’s National Medical Products Administration for treating chronic graft-versus-host disease (cGVHD). This development marks a significant milestone as Rovadicitinib progresses through Phase III clinical trials in China and Phase II trials in the U.S., showcasing promising results in earlier trials with high response and survival rates. The company aims to expedite global R&D efforts to provide better treatment solutions for patients worldwide.
Sino Biopharmaceutical Limited announced that its new drug, TQC3302, a triple-combination soft mist inhalation formulation for chronic obstructive pulmonary disease (COPD), has received clinical trial approval from China’s National Medical Products Administration. This development marks a significant step in the company’s efforts to provide advanced treatment options for COPD patients, as no similar formulation has been approved globally, potentially enhancing the company’s market position and offering new opportunities for stakeholders.
Sino Biopharmaceutical Limited has announced a board meeting scheduled for August 18, 2025, to approve the publication of its unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting could impact the company’s financial strategy and shareholder returns, reflecting its ongoing operational and financial planning.
Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, is progressing smoothly with its out-licensing collaboration with Merck & Co., Inc. for the LM-299/MK-2010 PD-1/VEGF Bispecific Antibody. The company is set to receive a US$300 million milestone payment following the successful technology transfer. This collaboration, which grants Merck exclusive global rights for LM-299, includes an upfront payment of US$588 million and potential milestone payments up to US$2.7 billion, highlighting Sino Biopharmaceutical’s strategic positioning in the global pharmaceutical market.
Sino Biopharmaceutical Limited announced that its subsidiary, LaNova Medicines, has received IND approval from the US FDA for LM-350, an innovative ADC targeting CDH17. This drug shows promise in treating various gastrointestinal tumors, particularly colorectal cancer, and highlights the company’s strong pipeline of ADC products in clinical and preclinical stages, potentially enhancing its industry positioning.
Sino Biopharmaceutical Limited has announced a supplemental update regarding its full acquisition of LaNova Medicines. The update includes additional information about the vendors involved in the transaction, such as QM162, Shanghai Jialang, and Summer Starry, which are backed by various venture capital and investment firms. The announcement also provides updated financial information for LaNova Medicines, reflecting the company’s ongoing efforts to strengthen its position in the healthcare industry through strategic acquisitions.
Sino Biopharmaceutical Limited has announced the successful first dosing of its self-developed Class 1 innovative drug, TQB6411, in a Phase I clinical trial in China. TQB6411 is a bispecific ADC targeting EGFR/c-Met, showing potential in treating various tumors such as non-small cell lung cancer and colorectal cancer. The drug has completed preclinical evaluations, demonstrating a clear anti-tumor mechanism and manageable toxicity risks. This development places Sino Biopharmaceutical among the leading global cohort in ADC drug development, with several other ADC projects in various stages of clinical trials.
Sino Biopharmaceutical announced the full acquisition of LaNova Medicines, increasing its equity stake from 4.91% to 100%, making LaNova an indirect wholly-owned subsidiary. The acquisition, valued at up to USD950.92 million, is a discloseable transaction under Hong Kong’s Listing Rules, indicating a strategic expansion in the company’s operations and market positioning.
Sino Biopharmaceutical Limited has announced the acceptance of its new indication application for the marketing of Culmerciclib Capsule, a CDK2/4/6 inhibitor, in combination with fulvestrant injection for the first-line treatment of HR-positive, HER2-negative advanced breast cancer. This acceptance by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC highlights the potential of this combination therapy in different stages of advanced breast cancer treatment, aligning with authoritative guidelines that recommend such therapies for this common subtype of breast cancer.
Sino Biopharmaceutical Limited has announced the approval of its self-developed drug, Anqixin®, a recombinant human coagulation factor VIIa for injection, by the National Medical Products Administration of China. This approval marks the first domestically produced product of its kind in China, offering an economical and high-quality treatment option for hemophilia patients with inhibitors. The drug’s efficacy and safety were confirmed through a Phase III clinical trial, demonstrating a hemostatic efficacy rate of 88.93%. The company has developed proprietary processes for production, ensuring quality consistency across batches, and holds patents for its innovative methods. This development positions Sino Biopharmaceutical as a significant player in the hemophilia treatment market, potentially benefiting a broader population of patients.
Sino Biopharmaceutical announced that its anlotinib hydrochloride capsules, combined with chemotherapy, have been approved by the National Medical Products Administration of China for first-line treatment of advanced or metastatic soft tissue sarcoma. This approval marks a significant milestone as it is the first combination therapy officially approved for this indication worldwide, showcasing the drug’s potential to improve treatment outcomes in a challenging cancer type. The approval is expected to enhance the company’s market positioning and provide new treatment options for patients, addressing unmet clinical needs in the field of soft tissue sarcoma.
Sino Biopharmaceutical Limited announced that its jointly developed drug, LM-108, a CCR8 monoclonal antibody, has been included in China’s Breakthrough Therapy Designation process for treating advanced gastric/gastroesophageal junction adenocarcinoma. The drug has shown promising results in clinical trials, demonstrating significant efficacy in overcoming resistance to PD-1/PD-L1 inhibitors and offering new treatment options for patients who have failed previous therapies. LM-108 is the most advanced CCR8 monoclonal antibody globally and is expected to become a next-generation immunotherapy for various tumors, potentially impacting the company’s market positioning and providing new hope for patients.
Sino Biopharmaceutical Limited announced promising results from preclinical and Phase Ib clinical studies of rovadicitinib, a novel treatment for acute graft-versus-host disease (aGVHD), presented at the 2025 European Hematology Association Congress. The drug, a dual JAK/ROCK pathway inhibitor, showed an overall response rate of 84.6% at 28 days and a 12-month survival rate of 92.3%. These findings suggest rovadicitinib as a potential alternative for patients with steroid-refractory aGVHD, highlighting its rapid and sustained response and the ability to reduce steroid use. The company has also initiated a Phase III trial for chronic GVHD, reinforcing its commitment to advancing treatment options in this field.
Sino Biopharmaceutical Limited announced that its self-developed Class 1 innovative drug, TDI01 suspension, has been included in the Breakthrough Therapy Designation process by China’s Center for Drug Evaluation. TDI01, a ROCK2 inhibitor, has shown significant efficacy and safety in treating moderate to severe chronic graft-versus-host disease (cGVHD) and is also being trialed for other conditions like idiopathic pulmonary fibrosis. This advancement underscores the company’s commitment to providing innovative treatment options and may enhance its position in the pharmaceutical industry.
Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, with a notable increase in revenue from innovative products and plans to launch several new products annually. The company is advancing multiple promising R&D pipelines, including drugs for chronic obstructive pulmonary disease, various cancers, and metabolic dysfunction-associated steatohepatitis, positioning itself as a leader in the biopharmaceutical industry.
Sino Biopharmaceutical Limited held its Annual General Meeting on June 10, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements for 2024, approval of a final dividend, re-election of directors, and authorization of the board to manage share capital and remuneration. The approval of these resolutions reflects strong shareholder support and positions the company for continued growth and stability in the biopharmaceutical sector.
Sino Biopharmaceutical has received approval from the Center for Drug Evaluation of China to initiate a Phase III clinical study for its innovative drug, TQB2868 injection, aimed at treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This drug, combined with anlotinib hydrochloride capsules and chemotherapy, has shown promising results in early trials, potentially becoming a groundbreaking first-line treatment option for pancreatic cancer, which currently has limited effective treatments and a low survival rate.
Sino Biopharmaceutical has announced that its innovative drug, TQC3721 inhalation suspension, has received approval from China’s National Medical Products Administration to commence a phase III clinical study for COPD treatment. This drug, a PDE3/4 inhibitor, offers both bronchodilatory and anti-inflammatory effects, potentially improving treatment outcomes for COPD patients. The approval marks a significant step in the company’s research and development efforts, positioning it as a leader in COPD treatment innovation. The study will evaluate the drug’s efficacy and safety across a broader patient base, which could enhance its market positioning and provide a competitive edge in the global pharmaceutical industry.
Sino Biopharmaceutical has announced the results of its phase III clinical study for benmelstobart injection, with or without anlotinib, as a maintenance treatment for non-small cell lung cancer (NSCLC) at the 2025 ASCO Annual Meeting. The study demonstrated a significant extension in median progression-free survival for patients receiving the combination treatment, marking a potential shift in clinical practice guidelines and offering new hope for NSCLC patients. The study’s findings have led to the acceptance of a marketing application for the new indication by the National Medical Products Administration of China, highlighting the potential impact on the company’s operations and industry positioning.
Sino Biopharmaceutical Limited announced the successful results of their phase III clinical study at the 2025 ASCO Annual Meeting, showcasing the efficacy of benmelstobart injection combined with anlotinib hydrochloride capsules as a first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC). The study, known as CAMPASS, demonstrated a significant improvement in progression-free survival (PFS) compared to pembrolizumab, with a notable 6.1-month prolongation in median PFS and a 40% reduction in the risk of disease progression or death in patients with TPS ≥50%. This advancement is expected to enhance first-line treatment options for PD-L1 positive advanced NSCLC patients in China, marking a significant clinical value in the oncology field.
Sino Biopharmaceutical Limited has announced promising preliminary results from a Phase II clinical study of its bi-functional fusion protein, TQB2868, combined with anlotinib and chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The study, presented at the 2025 ASCO Annual Meeting, showed significant improvements in objective remission and disease control rates compared to traditional chemotherapy regimens, with a favorable safety profile. This development could mark a significant breakthrough in pancreatic cancer treatment, potentially positioning TQB2868 as the first immune checkpoint inhibitor for first-line treatment, thereby improving patient survival and quality of life.
Sino Biopharmaceutical Limited has announced promising preliminary data from its phase I clinical study of TQB2102, a novel bispecific anti-HER2 antibody-drug conjugate, presented at the 2025 ASCO Annual Meeting. The study showed significant efficacy in treating various HER2-related cancers, including breast, colorectal, and gastric cancers, with a favorable safety profile compared to existing treatments. The ongoing phase III trials of TQB2102 are expected to potentially transform the treatment landscape for HER2 ADCs, offering a new therapeutic option with a lower incidence of adverse effects.
Sino Biopharmaceutical has announced positive results from its Phase III clinical study of Benmelstobart Injection combined with chemotherapy and Anlotinib for treating advanced squamous non-small cell lung cancer (sq-NSCLC). The study, presented at the 2025 ASCO Annual Meeting, showed a significant improvement in median progression-free survival and overall response rates compared to the control group. This breakthrough could potentially change the treatment landscape for sq-NSCLC, offering new hope for patients with limited options.